Biotech Values

[mcbio]

Given the much lower % sales dollars flowing to Momenta (than for Copaxone) apparently big pharma and Momenta either:

Even if terms of the deal result in a lower % sales dollar flowing to MNTA than for mC, don't you think these terms still may result in a large dollar amount flowing to MNTA on any one of these partnered FoBs? While I was hoping for better terms myself, the terms still allow the potential for a very meaningful dollar amount to flow to MNTA on any of these FoBs IMHO.